Vertex Pharmaceuticals (VRTX) Acquisitions (2009 - 2019)
Vertex Pharmaceuticals' (VRTX) quarterly Acquisitions came in at $908.4 million in Q4 2019, up 939.07% quarter-over-quarter from $87.4 million in Q1 2009.
Vertex Pharmaceuticals (VRTX) Acquisitions (2009 - 2019) Analysis & Trends
Vertex Pharmaceuticals' Acquisitions history runs 2 years deep, the most recent figure standing at $908.4 million for Q4 2019.
- On a quarterly basis, Acquisitions changed N/A year-over-year to $908.4 million in Q4 2019; TTM through Dec 2022 was $908.4 million, a 0.0% change from a year earlier, with the FY2022 full-year figure at $295.9 million, changed N/A from the prior year.
- Acquisitions rose to $908.4 million in Q4 2019 per VRTX's latest filing, from $87.4 million in the prior quarter.
- Across five years, Acquisitions topped out at $908.4 million in Q4 2019 and bottomed at $908.4 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 908.38 Mn |
| Mar 31, 2009 | 87.42 Mn |